Pharmabiz

Lokahi Therapeutics advances LT-100 development strategy toward single-injection administration

Lokahi Therapeutics advances LT-100 development strategy toward single-injection administration: Rutherford, New Jersey Friday, July 31, 2026, 17:00 Hrs [IST] Lokahi Therapeutics ...

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

RUTHERFORD, N.J. & LA JOLLA, Calif.-- (BUSINESS WIRE)--Jul 29, 2026-- ...

GlucoTrack Advances LT-100 to Single-Injection Development Strategy

GlucoTrack ( (GCTK) ) just unveiled an announcement.
Le Lézard

Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain

Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines, today announced the publication of positive results from the ...
Le Lézard

Onyx Security Raises $113M Series B to Control Advanced AI, Quadrupling Revenue since Stealth Launch Four Months Ago

Onyx Security, the AI control company, announced a $113 million Series B funding round led by Bessemer Venture Partners, with participation from Cyberstarts, TCV, Conviction, FirstMark, Vintage, ...
Nasdaq

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development ...

Tanning Influencers Push ‘Barbie Peptide.’ Here Are Risks Of Melanotan

Tanfluencers” have been touting the use of melanotan II—which has been dubbed the “Barbie peptide” but is not approved by the ...